In a move to increase shareholder value, ProMetic Life Sciences Inc. (TSX:PLI.SV), a leading biopharmaceutical company, today announced that its Board of Directors has approved a reorganization plan under which the business will be structured as a parent company with four pure-play operating units. Within the new structure, each distinct unit will function independently in terms of management, funding its operations, attracting investment, and developing specific products and services.
